Testing momelotinib for VEXAS syndrome
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests whether a new drug called momelotinib can help treat VEXAS syndrome, a rare genetic inflammatory condition. The study will see if it can reduce inflammation and allow patients to use less steroid medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You have a confirmed VEXAS diagnosis (genetic UBA1 mutation and signs of inflammation in at least one organ system within the past 6 months)
- You are currently taking steroid medication (prednisone or prednisolone) and have been taking it for at least 4 weeks
- You have not had more than one intensive care unit admission for a VEXAS flare in the past 6 months
- You do not have uncontrolled heart, lung, kidney, liver, or psychiatric conditions
- You are willing to stop other VEXAS treatments for a washout period before starting the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called arumakimig (MAS825) in people with VEXAS, a rare genetic condition that causes inflammation. The trial checks if the drug helps control symptoms and improve quality of life.
This trial tests a new drug called pacritinib for people with VEXAS syndrome, a rare autoinflammatory condition. The goal is to see if pacritinib can help control symptoms like rashes, joint pain, and low blood counts.
This trial looks for people age 50+ with unexplained inflammation or blood problems like anemia or low platelets. It aims to better identify a rare condition called VEXAS syndrome, which causes these symptoms.
This trial tests a drug called momelotinib for people with VEXAS syndrome, a rare inflammatory condition. The goal is to see if momelotinib can reduce symptoms and the need for steroids.
This Phase 2 trial tests whether an allogeneic stem cell transplant (from a donor) can treat VEXAS syndrome. It may help calm the body’s overactive inflammation and improve symptoms in eligible adults.
This study tests a new drug, momelotinib, for people with a low-risk form of myelodysplastic syndrome (MDS) who need red blood cell transfusions and have already tried one other treatment (like ESAs or luspatercept). The goal is to see if momelotinib can help reduce transfusion needs.
Hear when a new VEXAS Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.